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The immunological mechanisms that evolved for host defense against pathogens and 
injury are also responsible for transplant rejection. Host rejection of foreign tissue was 
originally thought to be mediated mainly by T cell recognition of foreign MHC alleles. 
Management of solid organ transplant rejection has thus focused mainly on inhibition of 
T cell function and matching MHC alleles between donor and host. Recently, however, it 
has been demonstrated that the magnitude of the initial innate immune responses upon 
transplantation has a decisive impact on rejection. The exact mechanisms underlying 
this phenomenon have yet to be characterized. Ischemic cell death and inflammation 
that occur upon transplantation are synonymous with extracellular release of various 
heat shock proteins (Hsps), many of which have been shown to have immune-modula-
tory properties. Here, we review the impact of Hsps upon alloimmunity and discuss the 
potential use of Hsps as accessory agents to improve solid organ transplant outcomes.
Keywords: Hsps, transplantation, alloimmunity, dendritic cells, immune regulation
inTRODUCTiOn
During organ transplantation, tissues are injured as a consequence of ischemia and reperfusion. 
Upon organ harvest, ischemia ensues and continues during organ preservation. Reperfusion 
happens upon anastomosis of graft vessels. Ischemia–reperfusion injury (IRI) induces cell death 
by necrosis and apoptosis leading to production of molecules denominated damage-associated 
molecular pattern (DAMPs) or alarmins (1). These are self, intracellular molecules, which are 
released by injured or necrotic cells under pathological conditions. In the extracellular environment, 
they can interact with and activate innate immune cells, acting as “danger signals” (2, 3). Resident 
macrophages and dendritic cells (DCs) are sensitive to DAMPs signals. These cells sense initial 
ischemic insults through pattern recognition receptors (PRRs). The engagement PRRs, including 
toll-like receptors (TLRs) and scavenger receptors (SRs), trigger intracellular signaling cascades 
that culminate in activation of transcription factors, which coordinate production of inflammatory 
cytokines and chemokines, upregulation of MHC and co-stimulatory molecules. DCs are the major 
antigen-presenting cells (APCs) and once activated in tissues, migrate to draining lymph nodes, 
and stimulate alloreactive T cell responses. DCs have to deliver three signals for optimal activa-
tion of T cells: (i) the expression of peptide:MHC complexes that will be recognized by the T cell 
receptor (TCR); (ii) co-stimulatory molecules; and (iii) cytokines that will shape T cell-mediated 
responses. Macrophages are also important contributors to IRI-induced inflammation and produce 
immune-stimulatory cytokines TNF-α, IL-1β, IL-6, and MCP-1, and chemokines which facilitate 
recruitment of alloreactive T-cells to the graft site (4, 5). While alloantigen-specific T cells are 
responsible for subsequent organ rejection and destruction, this outcome is very much shaped 
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by the local inflammatory state of the graft site (6). Thus, allo-
reactive immune responses result from activation of cellular 
components of both innate and adaptive immunity (7).
To improve the longevity of solid organ transplants, it is 
desirable to develop methods to limit IRI-induced inflamma-
tion and the ensuing alloreactive immune response. This review 
will discuss how heat shock proteins (Hsps) can modulate 
inflammatory and allogeneic immune responses, and how 
this can be harnessed to manage graft rejection in solid organ 
transplantation.
THe HeAT SHOCK ReSPOnSe AnD 
CYTOPROTeCTive PROPeRTieS OF Hsps
The heat shock response is universal and conserved from bacteria 
to mammals. It can be triggered by a range of protein-damaging 
conditions that affect organisms such as heat, anaerobiosis/
hypoxia, oxidative stress, inflammation, fever, and infection. 
Activation of the heat shock response is marked by upregulation 
of various Hsps. Under stress conditions, intracellular Hsps 
prevent protein aggregation, refold damaged proteins, and target 
damaged proteins for degradation. Under non-stress conditions, 
Hsps assist the folding of recently synthetized proteins, the trans-
location of proteins between organelles, and also regulate the cell 
cycle. These homeostatic functions of intracellular Hsps support 
proteome integrity and thereby promote cell viability. In addition, 
Hsps, such as Hsp70 and Hsp27, have been shown to negatively 
regulate multiple apoptotic signaling events including mito-
chondrial cytochrome c release (Hsp27), mitochondrial release 
of Smac (Hsp27), nuclear translocation of apoptosis-inducing 
factor (AIF) (Hsp70), and cleavage of procaspase 3 (Hsp70) 
(8–12). Hsps are conventionally grouped into families according 
to their molecular weight (e.g., Hsp40, Hsp70, and Hsp100) (13, 
14). Functional cooperation exists between family members; 
however, individual Hsp species perform distinct functions that 
can also be context dependent. In the context of IRI and organ 
transplantation, increased Hsp levels have been associated with 
cytoprotection, improvement of organ viability, and function 
after ischemia–reperfusion (15).
inTRACeLLULAR Hsps PROTeCT 
ALLOGRAFTS FROM  
iSCHeMiA–RePeRFUSiOn inJURY 
AnD iMPROve GRAFT SURvivAL
Increased levels of Hsps in transplant organ cells either by treat-
ment or genetic manipulation have been demonstrated to be ben-
eficial for transplant longevity (16). Hsps promote refolding of 
proteins denatured due to IRI, protecting cells from IRI-induced 
death. Hsp70 has been proposed to be the most potent anti-
apoptotic mediator inside the cell (17). Heat pre-conditioning of 
organs prior to transplant upregulates the expression of Hsps and 
prevents tissue damage from IRI by different mechanisms (18). 
Hsps’ cytoprotective capacity was also demonstrated in organs 
that were genetically modified to overexpress these proteins. 
Hearts from mice overexpressing Hsp27 induction correlated 
with increased survival when transplanted in fully MHC-
mismatched hosts (16). These hearts presented reduced caspase 
activation after subjection of ischemic/reperfusion conditions. 
In addition to heat, hypoxic pre-conditioning seems to reduce 
ischemic renal failure through a HIF-α/Hsp70 signaling pathway 
(19). This literature has been extensively reviewed in previous 
works (15, 20, 21).
Hsps CAn PROTeCT FROM iRi BY 
MODULATinG inFLAMMATiOn
Recently, several studies have highlighted a previously overlooked 
importance of innate cells in shaping T cell-mediated responses 
to alloantigens (5). Indeed, IRI and the subsequent intra-organ 
activation of innate cells have been shown to markedly enhance 
alloimmunity, contributing to poorer long-term outcomes and 
graft function. For example, delayed graft function (DRF) is a 
complication that occurs very early after the transplant procedure 
and results from a previous intense ischemic injury. Kidney trans-
plant patients with DRF have a higher risk to graft loss (22). Thus, 
strategies and treatments that prevent or decrease the activation 
of APCs by the released of ischemic-derived DAMPs could result 
in diminished alloimmunity and improve both early and late graft 
function (23).
During IRI, an important DAMP released by injured cells 
is the nucleotide adenosine triphosphate (ATP). Extracellular 
ATP (eATP) is recognized by purinergic receptors expressed by 
immune cells. Once eATP engages such receptors, it can trigger 
innate inflammatory responses and activation and prolifera-
tion of T cells. This can lead to further inflammation and cell 
damage, contributing to rejection [extensively reviewed in Ref. 
(24,  25)]. Additionally, high-mobility group box 1 (HMGB1) 
can also be released from dying cells. HMGB1 has been reported 
to be involved in IRI. HMGB-1 can activate APCs through 
TLR2 and TLR4 (26), as well as the receptor for advanced 
glycation end products (RAGE) (27), triggering anti-donor T 
cell responses (28).
Heat shock proteins have been suggested to act as DAMPs 
(29). Initial observations demonstrated that Hsps are elevated in 
transplanted organs, and Hsp-reactive T cells do infiltrate organs 
undergoing rejection (30). This raised the initial idea that such 
proteins play a crucial role as immunogenic antigens during 
alloimmune responses (15). Hsps are among many intracellular 
proteins that are released to the extracellular environment as a 
consequence of cell death during IRI. This is one reason why many 
consider Hsps to be DAMPS. Another reason is that extracellular 
isoforms of Hsps were reported by some studies to interact with 
TLRs and SRs and trigger inflammatory responses (31).
Aside from being passively released, Hsps can reach the 
extracellular milieu through different active pathways. Hsp70 
can be exported by an active non-classical secretory pathway, 
which cannot be blocked by inhibitors of the ER–Golgi pathway 
(32). Also, Hsp70 can be released by a lysosome–endosome 
mechanism, similar to IL-1β secretion (33), and a pathway 
involving secretory-like granules (34). Finally, Hsp70 can be 
secreted by a mechanism involving the insertion into exosome 
membranes (35).
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Thus, a scenario in which Hsps are found extracellularly 
during transplantation is likely, independently of passive or 
active release. More recent studies suggested that extracellular 
Hsps in transplants play additional immune roles – triggering 
anti-inflammatory responses and acting as immune modula-
tors. In  contrast to the DAMPs hypothesis, it was proposed 
that Hsps could belong to a group of molecules denominated 
resolution-associated molecular patterns (RAMPs) (36). RAMPs 
are released from necrotic and damaged cells, and when they 
reach the extracellular environment, will exert anti-inflammatory 
and regulatory effects over immune cells.
Resolution-associated molecular patterns are proposed to 
counterbalance acute inflammation and restore immune homeo-
stasis by modulating innate cells. After tissue damage, they can 
modulate acute inflammation by inducing the production of 
IL-10 (36). IL-10 has powerful anti-inflammatory and immune 
suppressive properties. It can modulate DCs activation and dif-
ferentiation, inhibits the release of inflammatory cytokines by T 
cells, APCs, and NK cells, and impairs cytotoxic ability of CD8 
T cells (37). The alpha B-crystallin (αBC) protein is considered 
a RAMP. Mice deficient for this protein have an exacerbated 
form of experimental autoimmune encephalomyelitis (EAE). 
Administration of αBC to mice with EAE reduces severity 
disease scores (38). Interestingly, and maybe not coincidentally, 
αBC is a chaperone, and a member of the small Hsps group. The 
induction of IL-10 by other Hsps, such as Hsp70 (39), Hsp60 
(40), and BiP (41), is well documented and has been reviewed 
elsewhere.
TRAnSPLAnT OF ORGAnS GeneTiCALLY 
MODiFieD TO OveReXPReSS Hsps 
GeneRATe LeSS inFLAMMATiOn
A member of the Hsp70 family that has immunomodulatory 
effects and acts as a RAMP is the endoplasmic reticulum (ER) 
protein GRP78 or BiP (38). When islet cells overexpressing 
GRP78 were transplanted in fully MHC-mismatched hosts, they 
presented decreased cell death, prolonged survival, and were less 
immunogenic compared with controls (42). In a murine cardiac 
transplant model, transgenic Hsp27 overexpression increased 
allograft survival. Hsp27tg-derived hearts exhibited reduced IRI-
induced apoptosis ex vivo and stimulated a reduced allogeneic 
inflammatory response compared with hearts transplanted from 
littermate controls (16). Markers for infiltrating T cells were 
reduced within transplanted hearts from Hsp27tg mice, and this 
was coupled with less production of IFN-γ day 5 post-transplant 
and increased IL-4 at day 2. In other inflammatory models, over-
expression of Hsps has also been shown to be beneficial not only 
due to their pro-survival roles but also by dampening inflamma-
tion. Overexpression of Hsp70 in transgenic (Tg) mice has been 
shown to protect animals from neuroinflammation (43). Hsp70 
overexpression can also induce neuroprotection from stroke and 
traumatic brain injury (44, 45). Consistent with Hsp70 possessing 
protective properties against tissue injury, Hsp70 Tg mice were 
found to have protection from inflammatory colitis and pulmo-
nary fibrosis in respective models compared with their wild-type 
counterparts (46, 47).
In summary, increased levels of Hsps can be beneficial 
through the prevention of cell death, precluding the release 
of DAMPs. It is also possible that in HspTg mice, after tissue 
damage is induced by transplantation, the concentration of 
extracellular Hsps released from damaged cells is higher, result-
ing in induction of tolerogenic responses and the dampening of 
inflammation.
Hsp PePTiDeS AS AnTiGenS FOR Treg 
CeLLS
Regulatory T cells (Tregs) can suppress excessive effector immune 
responses that are harmful to the host (48). Tregs can actively 
suppress innate and adaptive inflammatory immune responses 
through the production of the anti-inflammatory cytokines IL-10 
and/or TGF-β (49). Induction or administration of Tregs during 
transplantation is a promising approach for the management of 
allograft rejection (50). Although the peptide ligands for Tregs 
have not extensively been characterized, several studies have 
reported that they recognize self-peptides bound to MHC class 
II molecules (51). Tregs originate in the thymus (tTregs) but can 
also be induced at peripheral sites (pTregs) (52). For example, 
pTregs can be generated in a tolerogenic microenvironment by 
interacting with DCs producing anti-inflammatory cytokines 
and low levels of MHC II and co-stimulatory molecules (53).
Recently, it was shown that heat pre-conditioning of the organ 
had protective effects in acute kidney injury induced by IRI, and 
that protection was mediated by a direct immunomodulatory 
response of Hsp70-specific Tregs (54).
MODULATiOn OF ALLOGRAFT 
ReJeCTiOn BY eXTRACeLLULAR Hsps
In addition to benefits for transplant organs conferred by 
increased intracellular Hsp levels, a number of studies have now 
demonstrated various extracellular Hsps to also extend graft 
survival. For example, subcutaneous treatment of recipients 
prior to transplant with a single dose of full-length murine 
Hsp60 or with two of its peptides (p12 and p277) was found to 
prolong skin graft acceptance (55). Interestingly, no improve-
ment in skin allograft survival was observed when recipients 
were treated with an Hsp60 peptide from Mycobacterium 
tuberculosis (55). The authors suggested the differential effect 
between these Hsp60 species was likely due to a shift from an 
IFN-γ- to IL-10-producing phenotype in self-Hsp60-specific T 
cells, a shift which was not induced by treatment with myco-
bacterial Hsp60 (56). Consistent with skin graft protection 
conferred by mouse Hsp60 peptide administration, intranasal 
pre-treatment with encapsulated human Hsp60-derived peptide 
(p277) increased skin graft survival in two minor mismatched 
mice models (57). In this study, treatment with human Hsp60 
also induced production of the anti-inflammatory cytokine 
Il-10. Together the findings from these studies indicate that 
Hsp-mediated extension of graft survival may be closely related 
to IL-10 induction.
Heat shock protein 10 is an Hsp60 co-chaperone and was first 
described as early pregnancy factor (EPF) (58). This protein is 
FiGURe 1 | Beneficial effects of Hsps during transplantation. The upregulation of intracellular Hsps (iHsps) can protect cells from injury with a diminished 
release of DAMPs, decreased innate inflammation and less alloreactive T cell activation. The presence (in high concentrations) or administration of extracellular Hsps 
(eHsps) can also trigger immune-regulatory pathways on innate cells, favoring the generation of Tregs.
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found in pregnant women’s sera, and was described to be immu-
nosuppressive, involved in fetus tolerance (58). The subcutaneous 
in  situ delivery of recombinant Hsp10 improved skin allograft 
survival in rats (59). The authors suggested that Hsp10 would 
inhibit Th1 responses through donor DCs modulation (59).
Heat shock protein 70 (DnaK) from M. tuberculosis can 
improve graft survival in two different models of skin allografts. 
First, when the allogeneic B16F10 melanoma cells (H-2b/I-Ab) are 
subcutaneously injected in BALB/c hosts (H-2d/I-Ad), they are 
rejected due to MHC disparity. However, when those cells were 
injected in the presence of DnaK, they could form tumors in the 
hosts (60). In situ analysis demonstrated a tolerogenic environ-
ment with an increased infiltration of Tregs in DnaK-treated 
tumors, and depletion of Tregs abrogated DnaK-mediated tumor 
protection. Extracellular DnaK treatment of bone marrow-
derived macrophages (BMMs) was also found to promote the 
immunosuppressive M2-like macrophage phenotype and favor 
tumor growth in a murine melanoma model (61). Together, 
these studies demonstrated DnaK to have immunosuppressive 
effects upon multiple cell types. To exclude that the extended 
graft acceptance observed upon DnaK pre-treatment was due to 
other tumor mechanisms of immune evasion, we tested whether 
DnaK pre-treatment in situ impacted upon alloreactive responses 
in a fully MHC-mismatched skin graft model. We observed that 
DnaK-treated allografts had a significant increase in survival 
when compared with controls and in addition, this effect was 
dependent on Tregs (60, 62).
In addition to Hsp60 and Hsp70 family members, Hsp90 
proteins have also been shown to have protective properties. For 
example, subcutaneous treatment with mouse gp96 was shown 
to delay skin allograft rejection in minor and major mismatch 
models (63). In another study, intradermal treatment of heart 
transplanted rats with high doses of liver-purified gp96 from 
the donor strain prolonged graft survival. Treatment with gp96 
appeared to improve cardiac graft function immediately post-
transplantation. Interestingly, this treatment did not have an effect 
on graft survival if gp96 was derived from the host strain (64). The 
author’s proposed gp96 acted upon innate cells such as APCs, 
which led to a reduced T cell response and delayed rejection. As 
the delayed rejection effect was only observed when donor strain-
derived gp96 was used, we would suggest that it was donor cells 
that were subject to the immune-suppressive properties of gp96. 
The author did not exclude the gp96 effects upon graft longevity 
could be due to its wound-healing properties (64).
COnCLUSiOn AnD PeRSPeCTiveS
There is now substantial evidence to demonstrate the immuno-
suppressive potential of Hsps. These studies indicate that the anti-
inflammatory properties of Hsps warrant further investigation 
into Hsp-based treatments for contexts in which repression of 
immune responses is desirable. As discussed here, Hsp treatments 
have been effective agents to inhibit alloimmunity and extend 
solid organ transplant survival in mice. One could hypothesize 
Hsp treatments that promote a tolerogenic environment to also 
have therapeutic applications for various autoimmune and 
inflammatory diseases.
It remains to be seen how universal the application of immune-
regulatory properties of Hsps can be applied to transplants of dif-
ferent cells and tissues. It is also important to note that Hsps were 
reported to amplify inflammatory (31) and immune responses to 
tumor antigens (65). Thus, the impact of Hsps upon the resulting 
immune and inflammatory response currently appears to be very 
much context dependent (31).
In solid organ transplantation contexts, however, most stud-
ies have indicated higher levels of intracellular and extracellular 
Hsps extend graft survival. This is likely due to a combination 
of the cytoprotective properties of Hsps enabling better survival 
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following IRI and subsequent reduced DAMP release and inflam-
mation as well as the immunomodulatory effect extracellular Hsps 
have upon multiple cell types including macrophages, T cells, and 
DCs. The resulting Hsp-induced immuno-biology described has 
included modulation of APCs to induce tolerogenic responses 
and regulatory T cells and decreased alloreactive T cell generation 
(Figure 1).
Thus, ex vivo manipulation of organs before the transplant 
in order to increase Hsps levels could constitute a promising 
approach in decreasing initial ischemic damage and inflamma-
tion, improving organ survival. Administration of Hsp-derived 
peptides or ex vivo expansion of Treg with Hsp-derived peptides 
could be an alternative strategy to improve solid organ outcome. 
Elucidation of the innate cell subsets and the receptors by which 
Hsps can specifically interact with will be extremely important to 
optimize Hsp-based therapy design.
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